DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 020705
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
NDA 020705 describes RESCRIPTOR, which is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the RESCRIPTOR profile page.
The generic ingredient in RESCRIPTOR is delavirdine mesylate. One supplier is listed for this compound. Additional details are available on the delavirdine mesylate profile page.
The generic ingredient in RESCRIPTOR is delavirdine mesylate. One supplier is listed for this compound. Additional details are available on the delavirdine mesylate profile page.
Summary for 020705
| Tradename: | RESCRIPTOR |
| Applicant: | Viiv Hlthcare |
| Ingredient: | delavirdine mesylate |
| Patents: | 1 |
| Formulation / Manufacturing: | see details |
Pharmacology for NDA: 020705
| Mechanism of Action | Non-Nucleoside Reverse Transcriptase Inhibitors |
Medical Subject Heading (MeSH) Categories for 020705
Suppliers and Packaging for NDA: 020705
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705 | NDA | ViiV Healthcare Company | 49702-225 | 49702-225-17 | 180 TABLET in 1 BOTTLE (49702-225-17) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 100MG | ||||
| Approval Date: | Apr 4, 1997 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 200MG | ||||
| Approval Date: | Jul 14, 1999 | TE: | RLD: | Yes | |||||
| Patent: | Start Trial | Patent Expiration: | Jun 7, 2019 | Product Flag? | Substance Flag? | Delist Request? | |||
Expired US Patents for NDA 020705
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-001 | Apr 4, 1997 | Start Trial | Start Trial |
| Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-002 | Jul 14, 1999 | Start Trial | Start Trial |
| Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-002 | Jul 14, 1999 | Start Trial | Start Trial |
| Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-001 | Apr 4, 1997 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
